The role of the Val353 residue in antagonist binding to rat CCK-B receptors.
The Val353 residue of the rat cholecystokinin-B (CCK-B) receptor was mutated to Leu to test whether this residue is part of a binding site for antagonists having different chemical structures. The agonist radioligand [3H]SNF 8702 showed similar affinity for both wild-type and mutant receptors. Mutation of the CCK-B receptor reversed the order of affinities for the asperlicin derivatives from L-365,260 > devazepide (wild-type) to devazepide > L-365,260 (mutant) but had no effect on the affinity of the peptoid CCK-B receptor antagonist Cam-1028. The results show that Val353 is not part of a general CCK-B receptor antagonist recognition site and that Cam-1028 is recognized at a receptor site distinct from that binding asperlicin derivatives.